Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2165230 | 0.90 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNAGAAKMT2A | |
| SCHEMBL160329 | 0.84 | ALDH1A1 (0.58) | ALDH1A1MAPTLMNAGAAKMT2A | |
| SCHEMBL7659645 | 0.80 | MAPT (0.59) | ALDH1A1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL14288537 | 0.79 | HTT (0.50) | ALDH1A1MAPTLMNAGAAKMT2A | |
| SCHEMBL173546 | 0.76 | GAA (0.60) | ALDH1A1MAPTLMNAGAAKMT2A | |
| SCHEMBL14288535 | 0.75 | LMNA (0.44) | ALDH1A1MAPTLMNAGAAKMT2A | |
| SCHEMBL4863318 | 0.74 | AVPR2 (0.58) | LMNAPOLBADRB2ADRB1ADRB3 | |
| SCHEMBL4869903 | 0.74 | AVPR2 (0.58) | LMNAPOLBADRB2ADRB1ADRB3 | |
| SCHEMBL30204966 | 0.73 | MAPT (0.61) | ALDH1A1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL24792550 | 0.73 | MGLL (0.53) | ALDH1A1MAPTKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198284-B2 | Treatment of neurodegenerative disorders with thiourea compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-06-12 | — | — | US | disclosed |
| US-8198284-B2 | Treatment of neurodegenerative disorders with thiourea compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-06-12 | — | — | US | disclosed |
| US-8198284-B2 | Treatment of neurodegenerative disorders with thiourea compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-06-12 | — | — | US | disclosed |
| US-7985763-B2 | using an thiourea compound or carbonyl thiourea compound; therapy for drug resistant infections | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2011-07-26 | — | — | US | disclosed |
| US-7985763-B2 | using an thiourea compound or carbonyl thiourea compound; therapy for drug resistant infections | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2011-07-26 | — | — | US | disclosed |
| US-7985763-B2 | using an thiourea compound or carbonyl thiourea compound; therapy for drug resistant infections | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2011-07-26 | — | — | US | disclosed |
| US-20090275596-A1 | Treatment of Neurodegenerative Disorders with Thiourea Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| US-20090275596-A1 | Treatment of Neurodegenerative Disorders with Thiourea Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| US-20090275596-A1 | Treatment of Neurodegenerative Disorders with Thiourea Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| WO-2008124300-A1 | HEPATITIS C VIRUS INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124300-A1 | HEPATITIS C VIRUS INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-10-16 | — | — | WO | disclosed |
| US-20080255189-A1 | HEPATITIS C VIRUS INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-10-16 | — | — | US | disclosed |
| US-20080255189-A1 | HEPATITIS C VIRUS INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-10-16 | — | — | US | disclosed |
| US-20080255189-A1 | HEPATITIS C VIRUS INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275596-A1 | Treatment of Neurodegenerative Disorders with Thiourea Compounds | CLN6, MSR1, TPMT | ALDH1A1 1958/4885MAPT 27/4885LMNA 4754/4885 |
| US-20080255189-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, ZC3HAV1, ZC3HAV1L | ALDH1A1 4004/4885MAPT 2142/4885LMNA 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.